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Comorbidities refer to medical conditions or disorders
that exist in addition to an index disease. In the case
of head and neck cancer (HNC), comorbidities are dis-
eases that already exist in an individual at the time of
diagnosis of HNC, and can vary from patient to patient
as a result of genetic and environmental influences.
The significant association of tobacco and alcohol
as risk factors for the development of HNC, com-
bined with the advanced age of patients at the time of
HNC diagnosis, predispose HNC patients to increased
risks for comorbidities. Comorbidities are present in
21–35% of patients with HNC and have been shown
to be disproportionately higher in this group of patients
than in other cancer patient groups (except for lung
cancer, which ranks first with a 40% prevalence).1 The
most frequently encountered comorbidities in HNC
patients tend to be those that affect the pulmonary
and cardiovascular systems, which is not surprising
given the substantial use of tobacco and alcohol by
this group of patients. Datema et al2 identified ailments
most commonly found in the cardiovascular system
(32%), respiratory system (6.9%), gastrointestinal system
(7.2%), neurological system (4.2%) and endocrine
systems (3.9%) in 500 HNC patients in their retro-
spective cohort study in the Netherlands. Piccirillo et al3
also found pulmonary disease (17.9%), diabetes (7.9%),
and myocardial infarct (6.7%) to be the 3 most com-
mon comorbidities in their cohort of 1,094 patients
with squamous cell carcinoma of the head and neck.
With a significant incidence of comorbidities in
HNC patients already established, why is it important
to be cognizant of these comorbidities?
First, and most importantly, comorbidities have been
shown to significantly affect survival. A prospective study
by Piccirillo et al4 showed that survival was affected
by the severity of comorbidity as measured by the
Adult Comorbidity Evaluation-27 index (ACE-27; 
an index for assessing comorbidity where comorbidity
is rated as mild, moderate or severe). They found that
risks of 5-year mortality increased from 1.21 (95%
confidence interval, 1.13–1.30) for mild comorbidity to
2.56 (95% confidence interval, 2.35–2.81) for severe
comorbidity. Furthermore, a recent retrospective cohort
study by Homma et al5 on 156 patients diagnosed
with squamous cell carcinoma of the hypopharynx at 
a teaching hospital in Japan found a significant differ-
ence in 10-year survival (p = 0.0073) between patients
with “none” or “mild” comorbidity (45.1%) compared
with patients with “moderate” or “severe” comorbidity
(27.7%) as measured by the ACE-27.
Second, comorbidities have been shown to have an
impact on the quality of life (QoL) of HNC patients.
HNC patients are already predisposed to a poor QoL
due to the extent of surgical interventions (resulting in
speech, swallowing and cosmetic deficiencies that usually
tend to have psychosocial consequences) and nonsur-
gical interventions. With the added burden of comor-
bidities, it logically follows that QOL will be further
affected. This has been well corroborated by many stud-
ies, with a recent study by Terrell et al6 showing comor-
bidity to be one of the 2 strongest predictors of QoL
as measured by the Medical Outcomes Study 36-Item
Short-Form Health Survey7 (the other was the presence
of gastrostomy tubes).
Third, the severity of comorbidity has been shown
to significantly impact on the financial costs of HNC
management. With the presence of more medical
conditions increasing the number of required diag-
nostic and therapeutic interventions, it is not surpris-
ing that Hollenbeak et al8 found an increase in 5-year
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costs by $2,837 when a 1-point increase in severe
comorbidity (as measured by the Washington Uni-
versity Head and Neck Cancer Index) occurred.
While these findings indicate the significant role
that comorbidity plays in the course of HNC, what
could account for the infrequent and non-standard-
ized collection of comorbidity information in HNC
patients? One major reason could be the plethora of
comorbidity-assessing instruments that are currently
available for use, and therefore, the choice of instru-
ment becomes a dilemma for the health practitioner
or registrar attempting to collect comorbidity infor-
mation. For example, there are currently over 10 dif-
ferent types of comorbidity indexes.9 These include the
earlier-developed indexes such as the Kaplan-Feinstein
Index, the Charlson Comorbidity Index and more
recent indexes such as the ACE-27 Index and the
Elixhauser Comorbidity Index, which are modifications
of the earlier-developed indexes.
This issue is further complicated by the different
sources of comorbidity information (insurance claims-
based or chart-based) utilized by each of the instru-
ments. While some comorbidity indexes rely on the
International Classification of Disease codes (utilized
with insurance claims) for identifying the types of
comorbid ailments that may be present in a particular
patient, other indexes only require information that can
be gathered from elements (such as physician notes
and discharge summaries) of the medical chart.
Another problem is the unavailability of a standard-
ized registry for collecting longitudinal information
on HNC patients from the time of diagnosis up to sur-
vivorship. The absence of such a registry not only
impedes the type of foundational work that could
serve as an impetus for standardizing the collection 
of comorbidity (and other cancer-related) informa-
tion, but it also limits advances that could be made in
the management of HNC patients due to the wealth
of information such a registry could provide.
Our research group has recently completed the deve-
lopment of a validated online training module for the
collection of comorbidity information using the ACE-
27 Index,10 a validated instrument that uses a chart-
based approach to capture the existence and severity
(0=none, 1=mild, 2=moderate, 3= severe) of comor-
bid ailments. We have found that the use of this online
module demonstrates the ease and adaptability of the
ACE-27 to being used routinely for collecting comor-
bidity information. The module can be found at
http://oto2.wustl.edu/clinepi/comorbid.html under
“Comorbidity Coding Course”. The ACE-27 is just
one of the many indexes that may be adapted to rou-
tine use, but the important point to note is that
comorbidity information should begin to be collected
routinely.11
The challenges surrounding the efficient measure-
ment and collection of comorbidity information in
HNC patients are probably not limited to those dis-
cussed here. However, it is important for health care
teams to recognize these challenges. It is also important
to take steps in eliminating some of these challenges,
and this can initially be achieved by actively beginning
to collect comorbidity information. With the many
indexes available, the instrument of choice will of course
depend on site preference as well as the ease of utilizing
the index.
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